ABSTRACT
Quality of life (QoL) is becoming increasingly central to medical decision making for even the most aggressive and aggressively treated cancers and for settings in which life expectancy is short. Among patients with resectable pancreatic cancer, prognosis remains poor, with a 5-year overall survival rate of 10-20 %. 1, 2 Few data exist in the literature regarding QoL for pancreatic cancer patients, especially in the weeks and months after pancreatic resection, which carries a substantial risk of short-and long-term morbidity and often requires a prolonged recovery period. 3 High-quality data demonstrating the effects of resection on QoL from the perspective of the patient is invaluable for patient counseling and management. Previous studies have shown that familiarity with the expected postsurgical experience can reduce patients' surgical anxiety. 4, 5 In addition, such data would highlight common issues experienced during the postsurgical period that may call for monitoring or intervention, set a baseline for ''normal'' levels of morbidity, and inform comparisons between treatment options. 3 As the need for QoL assessment for pancreatic cancer patients became clear, the European Organization for Research and Treatment of Cancer (EORTC) developed a pancreatic cancer-specific module, the PAN26, to complement their widely used QoL instrument for cancer patients, the QLQ-C30. 6 The instrument has completed phases I-III of the EORTC module development process and is becoming the most commonly used pancreasspecific QoL instrument. [7] [8] [9] Despite the obvious benefits of QoL data generated from patients directly, patient-reported outcomes often are hard to interpret because in many cases, the measurement scales do not carry intrinsic meaning. For example, a score of 20 on the PAN26 pain scale carries no built-in interpretation as normal, good, or poor. Thus, a reader cannot picture what level of symptoms it represents.
In this analysis, we aimed to describe QoL before pancreatic resection and in the two subsequent months using a large, high-quality, prospectively collected phase 3 trial dataset. We also attempted to enhance the interpretability of the QoL outcomes through the use of data-driven anchors, which allow us to identify patients who experience a meaningful change from baseline in a given domain (clinically important worsening) versus an immaterial change. The primary analysis of this clinical trial demonstrated that pasireotide reduces pancreatic complications. 10 In this analysis, we were interested in the effect of complications on QoL and whether the confirmed efficacy of pasireotide to reduce complications would translate to improved QoL.
METHODS

Patients and Study Design
This was a secondary analysis of data collected in a phase 3, single-center, randomized, double-blind, placebocontrolled trial investigating the ability of preoperative subcutaneous pasireotide to reduce pancreatic complications. 10 The trial was approved by the institutional review board at Memorial Sloan Kettering Cancer Center.
Eligible patients were those undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy. Patients with a preoperative serum glucose level higher than 250 mg/dL, an international normalized ratio greater than 1.5, or a history of clinically significant cardiac disease were excluded from the study. Randomization was stratified by the operation performed (pancreaticoduodenectomy or distal pancreatectomy) and by the presence of preoperative pancreatic duct dilation (dilation was defined as a main duct diameter[4 mm at the site of pancreatic transection on preoperative imaging).
In this study, 900 lg of pasireotide or placebo was administered subcutaneously twice daily, starting on the morning of surgery and continuing for 7 days (14 doses). The patients were followed for surgical complications for 60 days using the Memorial Sloan Kettering Cancer Center (MSKCC) Surgical Secondary Events system. The primary end point of the study was pancreatic complications, defined as grade 3 or higher pancreatic fistula, pancreatic anastomotic leak, or intraabdominal abscess.
QoL Assessment
Quality of life was assessed preoperatively, then 14 and 60 days postoperatively using the EORTC QLQ-C30, which assesses QoL issues relevant to all cancer patients, and the PAN26, which addresses symptoms, treatment side effects, and emotional issues specific to pancreatic cancer. Surveys were completed in person at scheduled clinic visits. The C30 consists of 28 four-level Likert items and 2 seven-level Likert items, and the PAN26 consists of 26 four-level Likert items. Both instruments inquire about QoL currently or during the past week.
Statistical Analysis
The C30 items were scored according the EORTC scoring procedures to create six function scales (physical, role, emotional, cognitive, social, and global health status/ QoL) and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The PAN26 items were scored according to draft scoring procedures supplied by the EORTC to create one function scale (satisfaction with health care) and six symptom scales (pain, digestive symptoms, altered bowel habit, hepatic function, body image, and sexuality). 11 Higher scores are better for function scales and worse for symptom scales. The internal consistency of the hypothesized PAN26 scales was verified using Cronbach's alpha.
The scales were summarized using mean and standard deviation and compared across groups using t tests. For postoperative time points, scores were standardized by subtracting the baseline score. Differences between baseline and postoperative scores were assessed using paired t tests. For items that were not part of a scale, we reported the percentage of patients reporting any extent of symptoms (a little, quite a bit, or very much).
Clinically important worsening in score was defined for each domain as a worsening in score of at least 0.5 times the baseline standard deviation (baseline standard deviations are presented in Figs. 1, 2, 3) . Clinically important worsening is meant to capture differences that a patient would perceive as important and has been found to correspond with what clinicians would deem a ''moderate'' or larger effect. 12 All statistical analyses were performed with SAS 9.2 (SAS Institute, Cary, NC, USA) and R (R Foundation, Vienna, Austria). Two-sided p values lower than 0.05 were considered significant.
RESULTS
Survey Completion
The characteristics of the 300 evaluable patients have been described previously. 10 Questionnaires were completed at all time points by 87 % of the patients (260/300) and at each time point by 299, 273, and 265 patients, respectively. Preoperative, 14-and 60-day questionnaires were completed at a median of 6 days (range 0-40 days) before surgery, 16 days (range 8-49 days) postoperatively, and 62 days (range 39-112 days) postoperatively. Although some items were skipped, at least 76 % of the patients completed each domain. The least completed domain was PAN26 Sexuality.
Randomized Comparisons
The internal consistency of the PAN26 scales was assessed with standardized Cronbach's alpha and found to be adequate for all domains except hepatic function (data not shown). As expected, preoperative QoL was similar in the randomization groups ( Table 1 ). Shifting our focus to the QLQ-C30, pasireotide was associated with constipation at 60 days (p = 0.04) and social functioning at 14 days (p = 0.01). Pasireotide was not significantly associated with any other scale at 14 or 60 days (all p values [0.09; Table 1 ). Because only two significant differences were observed, because the differences were not consistent over time, and because the significance of these results would not stand up to adjustment for multiple comparisons, the placebo and pasireotide groups were combined for further analyses.
QoL Trajectory After Pancreatic Resection
A significant worsening of function was detected on all PAN26 scales except satisfaction and hepatic function at 14 days (Fig. 1) . At that time, 71 % of the patients experienced clinically important worsening, as shown by their scores on the PAN26 pain scale, and 66 % experienced clinically important worsening, as shown on the digestive symptoms scale. The percentage with clinically important worsening on other scales ranged from 24 to 52 %. Significant differences persisted at 60 days for most scales (pain, digestive symptoms, altered bowel habit, and body image), whereas sexuality returned to within 3 points of baseline. The scores at 14 and 60 days were significantly better than baseline values for the hepatic domain, although internal consistency at these time points was questionable.
Within the QLQ-C30 14 days after surgery, the scores were significantly worse than baseline values in all functioning domains except emotional (physical, role, cognitive, social and global health status) and in all symptom domains (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) (Figs. 2 and 3 ). The domains with the most patients experiencing clinically important worsening at 14 days were role functioning (83 % of patients), fatigue (81 % of patients), and physical and social functioning and pain FIG. 3 Quality of life on QLQ-C30 functioning domains following pancreatic resection. Each plot includes a boxplot of domain score (top half) and the percent of patients with a clinically important worsening (CIW) in score compared with preop (bottom half) (about 75 % of patients). By 60 days, cognitive functioning, nausea and vomiting, insomnia, and constipation were no longer significantly worse than baseline values, and there was no scale showing that more than 50 % of the patients still had clinically important worsening compared with baseline values. Emotional functioning actually improved following postoperative day 14 to become significantly better than at baseline by postoperative day 60 (p = 0.03).
Some questionnaire items are not used in the scoring of any domain. The percentages of patients experiencing problems in these fourteen areas are presented in Supplemental Table 1 . The patients were more likely to report problems at 14 days than at baseline or at 60 days. A high proportion of patients experienced some extent of future health worry (C85 % across all time points).
Effect of Pancreatic Complications
Pancreatic complications were associated with worse body image, physical, role, emotional, cognitive and social functioning, fatigue, C30 pain, dyspnea, insomnia, appetite loss, and financial difficulties at 14 days (Table 2) . Differences in clinically important worsening were especially pronounced for social functioning (93 % of patients with complications had clinically important worsening at 14 days vs 72 % of patients without complications), dyspnea (59 vs 29 %), and financial difficulties (60 vs 21 %). Differences in most of these domains also were seen at 60 days, and additionally, constipation and sexuality scores were worse for the patients with pancreatic complications,
DISCUSSION
Overall, we found that during the 14 days after resection, the patients experienced a significant decline in QoL. By 60 days, symptoms abated but generally remained significantly worse than at baseline, and emotional functioning was significantly better than at baseline. The areas of QoL especially affected were pain, digestive symptoms, fatigue, physical, role and social functioning. In each of All p values are from t tests of scores (baseline) and t tests of differences in score from baseline score (14-and 60-day). Means and p values are based on complete data. Scores range from 0 to 100 a A higher score is better; in all other cases, a lower score is better these areas, more than 65 % of the patients experienced clinically important worsening at 14 days. Our data shed light on the time required for recovery after resection. Our results are in line with those of previous studies that reported worse QoL immediately after surgery followed by a slow recovery to baseline values or better by 3-6 months postoperatively. [13] [14] [15] We found that pancreatic complications were associated with worse body image, dyspnea, financial difficulties, physical, role, and emotional and social functioning at 14 and 60 days. Although impaired QoL in the weeks after resection and impaired QoL associated with pancreatic complications are both to be expected, our data allowed us to quantify the extent of impairment that patients actually experience. It also is worth noting that the impact of complications on QoL persists for at least 2 months after the operation.
Although the primary analysis of this trial showed that pasireotide reduced the rate of pancreatic complications from 21 to 9 % and the analysis presented in this report shows that complications were associated with decline in several QoL domains, this did not appear to translate to measurably better QoL in this sample of patients. This may have been due to the fact that the majority of patients in both the placebo and pasireotide groups did not experience pancreatic complications. Although we can rule out a large effect of pasireotide on QoL, a study with a larger sample may have sufficient power to detect a small to moderate effect.
Future health worry was high in our study, with more that 85 % of the patients reporting some extent of worry across all three time points, as would be expected in the setting of a disease with high mortality. The patients reported significantly more financial difficulty after surgery than before and also more difficulty in the presence of pancreatic complications.
Although financial difficulties experienced by cancer patients are well documented, it is interesting that the level of concern changed with complications and over time. 16 Satisfaction with health care was generally high, and highest at 14 days postoperatively, probably because the patients had frequent interactions their health care team All p values are from t tests of difference in score from baseline score. In this study, 28 patients with PC and 245 patients without PC completed the 14-day questionnaire, whereas 36 patients with PC and 229 patients without PC completed the 60-day questionnaire PC pancreatic complications a A higher score is better; in all other cases, a lower score is better often in the days immediately after surgery, and memories of these positive experiences of the care they received would have been most recent at 14 days. Interestingly, emotional functioning was the only scale that significantly improved over time. (hepatic functioning also improved, but there were issues regarding the reliability of the scale.) This may have been due to the fact that patients are less anxious after their surgery has been successfully completed.
The strengths of this study included the use of a large (300 patients), high-quality randomized controlled trial dataset with high survey completion rates and the use of a diseasespecific instrument focused on issues unique to pancreatic cancer. Because published data from trials that used the PAN26 instrument are sparse, this study provides useful background data for future researchers. In addition, although the C30 and PAN26 scores themselves do not carry intrinsic meaning, we believe the use of clinically important worsening may make them more interpretable because this calculation is designed to represent a worsening in score large enough to be perceived as important by the patient.
One limitation of this analysis was that the data were collected for only 2 months after resection. With a longer followup period, we likely would have seen more domain scores return to baseline levels. Shaw et al. 17 used the C30 and PAN26 instruments to assess QoL in an unselected cohort of patients at a median of 42 months after pancreaticoduodenectomy and found that their scores compared favorably with those for control subjects undergoing cholecystectomy, with some differences suggestive of exocrine insufficiency. Additionally, in this analysis, we were unable to confirm the internal consistency of the hepatic scale of the PAN26, whereas the other scales had adequate internal consistency. The PAN26 instrument has not been validated with a large international cohort of patients, and future studies are needed to enhance understanding of its properties and to thoroughly assess its reliability and validity.
In conclusion, this study used empirical data to characterize the decrease in QoL after pancreatectomy as reported by patients themselves. During the 2 weeks after resection, patients can be expected to have a significant decline in QoL. The data from this study suggest that many symptoms abate by 60 days and that emotional functioning improves. A measurable decrease in QoL was observed in the patients who experienced pancreatic complications, but the decrease in pancreatic complications observed in the group who received pasireotide did not translate to a measurable improvement in QoL.
